Trial Profile
An Open-Label Phase 1 Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment When Applied Twice Daily for 28 Days in Male and Female Patients With Basal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BIL 010t (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Biosceptre International
- 02 Feb 2017 Results published in the British Journal of Dermatology
- 04 Sep 2014 New trial record